oncogenic function by inhibiting EYA4 expression and may be potentially useful for a prognostic biomarker. These results also suggest that miR-224 may have therapeutic potential target for the treatment of CCRCC.
INTRODUCTION AND OBJECTIVES: CRISPR/Cas9 technology was introduced as an efficient, powerful and broadly used genome editing tool. The aim of this study was to utilize the CRISPR/Cas9 system to control miRNA expression in cancer research.
METHODS: In our miRNA expression signatures in clear cell renal cell carcinoma (ccRCC), we focused on miR-210-3p which was one of the most upregulated miRNAs. We used lenti-CRISPR vector to knock out miR-210-3p with two different single guide RNAs against miR-210-3p. We performed cell function studies and xenograft assay with miR-210-3p-depleted cells. Putative target genes of miR-210-3p was examined in miRNA binding assay. In addition, overall survival between high and low expression of miR-210-3p or the target gene were analyzed by the Kaplan-Meier method.
RESULTS: In cells transfected with sgRNA targeting miR-210-3p itself, more than 98% miR-210-3p knock out efficiency was observed in all three cell lines (786-o, A498 and Caki2). miR-210-3p depletion significantly increased invasive capacity (P < 0.01) in vitro, and dramatically promoted tumorigenesis in xenograft experiments (P ¼ 0.0039), which was unexpected due to the fact that these miRNAs were up-regulated in RCC. We also found that twist family bHLH transcription factor 1 (TWIST1) was identified as a direct target of miR-210-3p based on target analyses (P < 0.05). The Cancer Genome Atlas (TCGA) database of ccRCC showed that there was a negative correlation between miR-210-3p and TWIST1 expression (P < 0.0001). In accordance with the results in vivo and in vitro analyses, TCGA database showed that the low miR-210-3p expression group had poor survival in comparison with the high group, and the high TWIST1 expression group had poor overall (P ¼ 0.00054) and disease-free survival (P ¼ 0.00347) compared to the low expression group significantly.
CONCLUSIONS: We utilized the CRISPR/Cas9 system to analyze an upregulated miRNA in cancer. CRISPR/Cas9 successfully suppressed miR-210-3p expression in RCC cells. Moreover, by using CRISPR/Cas9 techniques, we found that tumorigenesis was acquired through enhanced expression of oncogenic TWIST1 due to the suppression of miR-210-3p expression via CRISPR/Cas9 techniques. The introduction of the CRISPR/Cas9 methodologies into studies of miRNAs as well as other non-coding RNAs should provide new possibilities in cancer research.
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OVEREXPRESSION OF CYP1B1 MEDIATED BY LOSS OF MIR-200C PROMOTES RENAL CELL CARCINOMA TUMORIGENESIS VIA ALTERED EXPRESSIONS OF CDC20 AND DAPK1
Yozo Mitsui*, Tokyo, Japan; Inik Chang, Seoul, Korea, Republic of; Koji Tamura, Toshihiro Tai, Masato Nagata, Fumito Yamabe, Kuri Suzuki, Hideyuki Kobayashi, Koichi Nagao, Koichi Nakajima, Tokyo, Japan; Rajvir Dahiya, Yuichiro Tanaka, San Francisco, CA INTRODUCTION AND OBJECTIVES: Cytochrome P450 1B1 (CYP1B1) has been shown to be up-regulated in many types of cancer including renal cell carcinoma (RCC), while several reports have shown that CYP1B1 influences regulation of tumor development. However, its role in RCC development has not been elucidated. Here, we explored the functional role and regulatory mechanism of CYP1B1 in RCC.
METHODS: CYP1B1 expression was determined in RCC cell lines, and microarray findings of 96 RCC and 25 normal tissues were obtained. To examine the biological significance of CYP1B1 in RCC progression, we silenced the gene in Caki-1 and 769-P cells by RNA interference, and performed various functional analyses. Furthermore, we evaluated whether miR-200c expression, significantly down-regulated in RCC, is associated with CYP1B1 level in both clinical samples and cell lines.
RESULTS: First, we confirmed that CYP1B1 protein expression was significantly higher in RCC cell lines as compared to normal kidney tissues, a trend that was also observed in RCC tumor samples (p<0.01). Furthermore, CYP1B1 expression was associated with tumor grade and stage. Next, we silenced the gene in Caki-1 and 769-P cells by RNA interference, and performed various functional analyses to determine the biological significance of CYP1B1 in RCC progression. Inhibition of CYP1B1 expression resulted in decreased cell proliferation, and migration and invasion of RCC cells, while that also induced apoptosis of Caki-1 cells. In addition, gene microarray findings indicated that the anti-tumor effects on RCC cells caused by CYP1B1 depletion might have been due to alteration of CDC20 and DAPK1 expressions, which was confirmed by real-time PCR. Interestingly, CYP1B1 expression was associated with CDC20 and DAPK1 expressions in the clinical samples. Finally, we found that CYP1B1 level was inversely correlated with miR-200c expression in RCC, and miR-200c directly targets the CYP1B1 3 0 -UTR and regulates its expression.
CONCLUSIONS: CYP1B1 up-regulation mediated by reduced expression of miR-200C may promote RCC development by inducing CDC20 expression and inhibiting apoptosis via down-regulation of DAPK1. Our results demonstrate that CYP1B1 and miR-200c are potential tumor biomarkers and targets for anticancer therapy in RCC patients. 197, No. 4S, Supplement, Sunday, May 14, 2017 patients have distal metastasis at the time of diagnosis. Despite great improvement in therapeutic treatment including molecular targeted therapy, the prognosis of patients with distant metastases remains unfavorable. HOX transcript antisense RNA (HOTAIR) is one of the long non-coding RNAs (lncRNAs). Accumulating evidence demonstrates that HOTAIR plays essential roles in cancer development and metastasis in several types of cancer such as lung cancer and gastric cancer. However, the precise mechanism by which HOTAIR enhances cancer malignancy is still unknown, especially in RCC. The object of this study is to elucidate the function of HOTAIR in RCC. METHODS: The tumor and adjacent normal renal tissues were obtained with informed consent from 64 patients who underwent radical or partial nephrectomy in Miyagi Cancer Center. All tumor tissues were diagnosed pathologically as clear cell renal cell carcinoma. We evaluated the clinical correlates of HOTAIR expression determined by realtime PCR using RNA extracted from the tumor and normal tissues. The functional role of HOTAIR was examined using HOTAIR-overexpressing or knockdown human renal cell carcinoma cell lines (ACHN, A498 and Caki-1).
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RESULTS: The expression of HOTAIR was significantly correlated with tumor nuclear grade, lymph node metastasis, lung metastasis, and AJCC stage. Migration capacity was enhanced in a HOTAIR-depending manner in vitro. Overexpression of HOTAIR in human renal cell carcinoma accelerated tumorigenicity in immunodeficient mice. Microarray analysis revealed that Insulin Growth Factor Binding Protein 2 (IGFBP2) gene was up-regulated in HOTAIR-overexpressing cells, which was validated by real-time PCR and Western blotting. Co-expression of IGFBP2 and HOTAIR was observed in clinical samples (P ¼ 0.04, Fisher 0 s exact test). Enhanced migration activity in HOTAIR-expressing cells was attenuated by IGFBP2knockdown.
CONCLUSIONS: We newly identified IGFBP2 as a downstream molecule of HOTAIR, which is involved in migration capacity. Our findings suggest that a HOTAIR-IGFBP2 axis plays critical roles in RCC progression, and serves as a novel therapeutic target for advanced RCC treatment. of various human malignancies. However, the function of lncRNAs and their underlying mechanism in renal cell carcinoma ( RCC ) is still unraveled. The aims of this study were to investigate the expression of lncRNA BX357664 in RCC and explore its function in RCC cell lines.
Source of
METHODS: Previous microarray analysis was used to screen potential deregulated lncRNA. Real-time qualitative PCR (qRT-PCR) was used to further confirm the deregulation of BX357664 in 40 paired human RCC samples. Ability of migration, invasion and proliferation in RCC cells were detected by cell migration and invasion assay, cell proliferation assay and cell cycle assay. Western blot was performed to identify the influence of BX357664 on epithelialmesenchymal transition (EMT), MMP9 and TGF-beta 1/p38/HSP27 signaling pathway in RCC.
RESULTS: BX357664 was downregulated in tumor tissues in previous microarray analysis (P < 0.05), qRT-PCR was further performed to validate the BX357664 expression in 40 paired RCC tissues and adjacent normal tissues. The result was consistent with the microarray data(P < 0.05). Meanwhile, BX357664 expression was significantly lower in RCC cell lines (Caki-1 and Caki-2) compared with normal renal cell line HK-2(P < 0.05). After upregulation of BX357664 in RCC celllines, ability of migration, invasion and proliferation in RCC cells were significantly inhibited(P < 0.05). In addition, overexpression of BX357664 could block EMT, MMP9 through inhibiting TGF-beta 1/ p38/HSP27 signaling pathway. Subsequently, upregulating the protein level of TGF-beta 1 with the present of BX357664 could rescue the malignant cell behaviors inhibited by BX357664 which indicated that BX357664 was attributed its inhibitory role to suppression of TGFbeta 1.
CONCLUSIONS: We have revealed a novel lncRNA BX357664, which might exhibit its inhibitory role in RCC metastasis and progression via block TGF-beta 1/p38/HSP27 pathway.
